<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Zubsolv</title>
    <link rel="shortcut icon" href="images/testlogo.png" type="image/x-icon">
    <link rel="stylesheet" href="css.css">
    <style>
        body {
            background-color: rgba(196, 241, 255, 0.562);
        }
        .container {
            text-align: center;
            margin-left: 100px;
            margin-right:100px;
        }
        p {
            font-size: 22px; /* Adjust the font size as desired */
            font-style: italic;
            text-align: justify;
            text-justify: inter-word;
          }
          table {
         border-spacing: 30px;
          }
    </style>
</head>
<body>
    <center>
        <h1>Zubsolv</h1><br>
        <table>
            <tr>
                <td><img src=" 
                    https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1-image-31.jpg"
 width="300px" height="200px"  alt=""></td>

            </tr>
        </table>
            <div class="container">
                    <p>Zubsolv is a medication that is used for the treatment of opioid dependence. It is a prescription sublingual tablet that contains a combination of buprenorphine and naloxone.Zubsolv is usually taken sublingually, which means it is placed under the tongue and allowed to dissolve.


                        .</p>
            </div>
    </center>
    
</body>
</html>